Retatrutide, Aleniglipron, and the End of Wegovy’s Reign: The Obesity Drug Data Bombshells from ADA 2026

The American Diabetes Association’s 86th Scientific Sessions in New Orleans didn't just showcase new data—it fundamentally redrew the competitive map of the obesity drug market. The clear message from the meeting was that the efficacy ceiling has been smashed, the oral GLP-1 race is now a two-front war, and the investment case for next-generation obesity treatments is no longer about just weight loss, but full-spectrum cardiometabolic disease modification.

Eli Lilly solidifies its lead with a one-two punch

Eli Lilly arrived at ADA 2026 with two programs that reinforced its dominance in both injectable and oral obesity treatments.

Retatrutide, a first-in-class weekly injectable that simultaneously activates GIP, GLP-1, and glucagon receptors, delivered what multiple conference reports described as the highest weight-loss efficacy of any pharmacological agent in a recent trial . In the pivotal Phase 3 TRIUMPH-1 trial, adults with obesity on the 12 mg dose lost an average of 70.3 lbs, or 28.3% of their body weight, over 80 weeks . Simultaneous publication added scientific weight to the presentation . The TRANSCEND-T2D-1 trial in adults with type 2 diabetes showed an A1C reduction of up to 2.0% alongside weight loss of up to 36.6 lbs . Across its massive Phase 3 program—encompassing 14 trials and more than 22,000 participants—retatrutide is being investigated for obesity, type 2 diabetes, knee osteoarthritis, and obstructive sleep apnea, with regulatory submissions expected in 2026 .

Foundayo (orforglipron), Lilly’s oral once-daily GLP-1 agonist, established its lead in the pill-based segment. The company announced that Foundayo has completed seven positive Phase 3 trials, with six more ongoing . It is marketed as the only oral GLP-1 taken without food or water restrictions . At ADA, post-hoc analyses of over 1,500 women across the ATTAIN-1 and ATTAIN-2 trials showed significant weight loss at every stage of menopause, a finding that broadens the addressable patient population . Lilly also reported clinical superiority over leading oral competitors for both A1c reduction and weight management in type 2 diabetes .

Structure Therapeutics disrupts the oral GLP-1 race

Structure Therapeutics emerged as the most serious challenger to the oral GLP-1 incumbents with its once-daily small-molecule agonist aleniglipron. The presentation of the Phase 2b ACCESS II data, concurrently published in Nature Medicine, sent a clear signal: oral efficacy is now approaching injectable territory. At 44 weeks, aleniglipron demonstrated up to 16.3% body weight loss, which the company described as the highest efficacy among oral GLP-1 receptor agonists at that time point and potentially comparable to injectable GLP-1 therapies . At 56 weeks in an open-label extension, weight loss reached up to 16.2% with no apparent plateau, suggesting continued benefit with longer treatment duration . The tolerability profile showed a 10.4% discontinuation rate due to adverse events, a metric closely watched by clinicians evaluating real-world adherence . Phase 3 is on track to start in Q3 2026 .

Novo Nordisk fights back—but faces an efficacy gap

Novo Nordisk brought its own next-generation contender, CagriSema, a fixed-dose combination of semaglutide and the long-acting amylin analog cagrilintide. The full Phase 3 REIMAGINE 2 results, presented in a dedicated symposium, showed superior outcomes over semaglutide monotherapy: a 1.91 percentage-point HbA1c reduction and 14.2% mean weight loss over 68 weeks in 2,728 adults with type 2 diabetes . This was the first head-to-head Phase 3 data for the dual agonist .

The company also presented a wide-ranging package of post-hoc analyses from the SELECT, STEP, ESSENCE, and OASIS trials, reinforcing semaglutide’s cardiometabolic benefits in conditions including asthma and hypertension . In a separate commercial update, Novo Nordisk disclosed that prescriptions for the Wegovy pill have surpassed 3 million since its January 2026 launch, with more than 80% of new prescriptions going to people new to GLP-1 therapy—evidence that the oral formulation is expanding rather than cannibalizing the market .

Despite these strengths, the available conference reporting consistently framed Lilly’s retatrutide as setting the highest pharmacological weight-loss benchmark . CagriSema’s 14.2% weight loss is a meaningful improvement over semaglutide alone, but it does not close the gap with retatrutide’s 28.3%. Novo retains a credible next-generation injectable strategy, but the efficacy narrative now belongs to Lilly.

AstraZeneca: a notable absence

Across all supplied ADA 2026 sources, AstraZeneca did not register as a headline obesity player. No major obesity-specific pipeline results from the company were featured in the conference’s main readouts or in competitive assessments. This absence suggests that, at least at this meeting, AstraZeneca was not among the top-tier competitors reshaping the market.

What it all means for the market

Three structural shifts became unmistakable at ADA 2026:

• Efficacy benchmarks moved beyond pharmacology toward surgery. Retatrutide’s 28%+ weight loss at 80 weeks now rivals outcomes from bariatric surgery, reshaping the risk-reward calculus for patients, payers, and investors .
• Oral GLP-1s are a battleground, not a niche. With Foundayo completing seven Phase 3 trials and aleniglipron showing 16%+ efficacy in Phase 2b, the oral segment is attracting serious competitive investment. The tolerability and convenience of oral small molecules could expand the treated population dramatically .
• Obesity drugs are now cardiometabolic franchise plays. Survodutide’s Phase 3 data in both obesity and MASH, along with retatrutide’s investigation in osteoarthritis and sleep apnea, show that the next generation of drugs will be approved on the strength of multi-indication outcomes, not weight loss alone .

Eli Lilly’s combination of injectable dominance with retatrutide and oral leadership with Foundayo positions it as the clear frontrunner. Structure Therapeutics has the momentum to become a credible disruptor if Phase 3 data confirm the Phase 2b signal. Novo Nordisk, while commercially strong with Wegovy and oral semaglutide, must contend with an efficacy gap that its next-generation CagriSema has not yet closed. The next data catalysts—including aleniglipron’s Phase 3 launch and retatrutide’s regulatory submissions—are already reshaping investor attention as the market enters the second half of 2026.

The article draws on conference reporting, corporate announcements, and regulatory filings to provide a source-grounded competitive assessment. All efficacy figures reflect the specific trial populations and time points reported by each company.